FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947771817> ?p ?o ?g. }

• W2947771817 endingPage "e956" @default.
• W2947771817 startingPage "e946" @default.
• W2947771817 abstract "Background Cabazitaxel has been shown to improve overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients after docetaxel in the TROPIC trial. However, trial populations may not reflect the real-world population. We compared patient characteristics and outcomes of cabazitaxel within and outside trials (standard of care, SOC). Patients and Methods mCRPC patients treated with cabazitaxel directly after docetaxel therapy before 2017 were retrospectively identified and followed to 2018. Patients were grouped on the basis of treatment within a trial or SOC. Outcomes included OS and prostate-specific antigen (PSA) response. Results From 3616 patients in the CAPRI registry, we identified 356 patients treated with cabazitaxel, with 173 patients treated in the second line. Trial patients had favorable prognostic factors: fewer symptoms, less visceral disease, lower lactate dehydrogenase, higher hemoglobin, more docetaxel cycles, and longer treatment-free interval since docetaxel therapy. PSA response (≥ 50% decline) was 28 versus 12%, respectively (P = .209). Median OS was 13.6 versus 9.6 months for trial and SOC subgroups, respectively (hazard ratio = 0.73, P = .067). After correction for prognostic factors, there was no difference in survival (hazard ratio = 1.00, P = .999). Longer duration of androgen deprivation therapy treatment, lower lactate dehydrogenase, and lower PSA were associated with longer OS; visceral disease had a trend for shorter OS. Conclusion Patients treated with cabazitaxel in trials were fitter and showed outcomes comparable to registration trials. Conversely, those treated in daily practice showed features of more aggressive disease and worse outcome. This underlines the importance of adequate estimation of trial eligibility and health status of mCRPC patients in daily practice to ensure optimal outcomes." @default.
• W2947771817 created "2019-06-07" @default.
• W2947771817 creator A5007432314 @default.
• W2947771817 creator A5019942881 @default.
• W2947771817 creator A5025436719 @default.
• W2947771817 creator A5029408018 @default.
• W2947771817 creator A5036825889 @default.
• W2947771817 creator A5038426869 @default.
• W2947771817 creator A5039709555 @default.
• W2947771817 creator A5040190541 @default.
• W2947771817 creator A5041610986 @default.
• W2947771817 creator A5056550523 @default.
• W2947771817 creator A5058463503 @default.
• W2947771817 creator A5063553660 @default.
• W2947771817 creator A5067473544 @default.
• W2947771817 creator A5073223699 @default.
• W2947771817 creator A5074784071 @default.
• W2947771817 creator A5082610769 @default.
• W2947771817 creator A5083250783 @default.
• W2947771817 creator A5085138741 @default.
• W2947771817 creator A5086184099 @default.
• W2947771817 creator A5091818868 @default.
• W2947771817 date "2019-10-01" @default.
• W2947771817 modified "2023-10-01" @default.
• W2947771817 title "Second-Line Cabazitaxel Treatment in Castration-Resistant Prostate Cancer Clinical Trials Compared to Standard of Care in CAPRI: Observational Study in the Netherlands" @default.
• W2947771817 cites W1606511994 @default.
• W2947771817 cites W1884893528 @default.
• W2947771817 cites W1980278232 @default.
• W2947771817 cites W1991233593 @default.
• W2947771817 cites W2003445255 @default.
• W2947771817 cites W2004523378 @default.
• W2947771817 cites W2031825421 @default.
• W2947771817 cites W2036601083 @default.
• W2947771817 cites W2077447317 @default.
• W2947771817 cites W2077895617 @default.
• W2947771817 cites W2110534364 @default.
• W2947771817 cites W2111879252 @default.
• W2947771817 cites W2120292596 @default.
• W2947771817 cites W2123526148 @default.
• W2947771817 cites W2133099372 @default.
• W2947771817 cites W2138190524 @default.
• W2947771817 cites W2138881017 @default.
• W2947771817 cites W2140056658 @default.
• W2947771817 cites W2141454098 @default.
• W2947771817 cites W2148643283 @default.
• W2947771817 cites W2237016546 @default.
• W2947771817 cites W2278392405 @default.
• W2947771817 cites W2508779833 @default.
• W2947771817 cites W2520035349 @default.
• W2947771817 cites W2527922674 @default.
• W2947771817 cites W2530746957 @default.
• W2947771817 cites W2566519800 @default.
• W2947771817 cites W2748586176 @default.
• W2947771817 cites W2762323160 @default.
• W2947771817 cites W2792310205 @default.
• W2947771817 cites W2794456310 @default.
• W2947771817 cites W2805401353 @default.
• W2947771817 cites W2885183647 @default.
• W2947771817 cites W4205145397 @default.
• W2947771817 cites W4242593516 @default.
• W2947771817 cites W962578561 @default.
• W2947771817 doi "https://doi.org/10.1016/j.clgc.2019.05.018" @default.
• W2947771817 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31439536" @default.
• W2947771817 hasPublicationYear "2019" @default.
• W2947771817 type Work @default.
• W2947771817 sameAs 2947771817 @default.
• W2947771817 citedByCount "5" @default.
• W2947771817 countsByYear W29477718172021 @default.
• W2947771817 countsByYear W29477718172022 @default.
• W2947771817 countsByYear W29477718172023 @default.
• W2947771817 crossrefType "journal-article" @default.
• W2947771817 hasAuthorship W2947771817A5007432314 @default.
• W2947771817 hasAuthorship W2947771817A5019942881 @default.
• W2947771817 hasAuthorship W2947771817A5025436719 @default.
• W2947771817 hasAuthorship W2947771817A5029408018 @default.
• W2947771817 hasAuthorship W2947771817A5036825889 @default.
• W2947771817 hasAuthorship W2947771817A5038426869 @default.
• W2947771817 hasAuthorship W2947771817A5039709555 @default.
• W2947771817 hasAuthorship W2947771817A5040190541 @default.
• W2947771817 hasAuthorship W2947771817A5041610986 @default.
• W2947771817 hasAuthorship W2947771817A5056550523 @default.
• W2947771817 hasAuthorship W2947771817A5058463503 @default.
• W2947771817 hasAuthorship W2947771817A5063553660 @default.
• W2947771817 hasAuthorship W2947771817A5067473544 @default.
• W2947771817 hasAuthorship W2947771817A5073223699 @default.
• W2947771817 hasAuthorship W2947771817A5074784071 @default.
• W2947771817 hasAuthorship W2947771817A5082610769 @default.
• W2947771817 hasAuthorship W2947771817A5083250783 @default.
• W2947771817 hasAuthorship W2947771817A5085138741 @default.
• W2947771817 hasAuthorship W2947771817A5086184099 @default.
• W2947771817 hasAuthorship W2947771817A5091818868 @default.
• W2947771817 hasBestOaLocation W29477718172 @default.
• W2947771817 hasConcept C121608353 @default.
• W2947771817 hasConcept C126322002 @default.
• W2947771817 hasConcept C143998085 @default.
• W2947771817 hasConcept C207103383 @default.
• W2947771817 hasConcept C2776551883 @default.
• W2947771817 hasConcept C2777899217 @default.

• next